Major Advance: PARP Inhibitor Pill Extends Life For Women With High Risk Breast Cancer & BRCA Mutations

Updated November 5th, 2021

Major Advance: PARP Inhibitor Pill Extends Life For Women With High Risk Breast Cancer & BRCA Mutations

A major new study has found that for women with early stage breast cancer classified as (HER2)–negative, who also have one of the mutations from the BRCA gene, a relatively new class of drugs called PARP Inhibitors significantly extends life after initial treatment.

NOW
PLAYING
'JoJo's Bizarre Adventure' Star Billy Kametz, 35, Announces Stage 4 Colon Cancer, Will 'Take Time Off' Show
NOW
PLAYING
Robin Roberts, 61, Says Partner Amber Laign, 47, Had to Pause Her Breast Cancer Treatments Due To 'Complications'
NOW
PLAYING
How Does a Patient Best Reduce the Risk of Breast Cancer Recurring?
NOW
PLAYING
She Gave Her Boyfriend a Chance to Bounce After Her Cancer Diagnosis; He Chose to Stay Put and Blew Her Mind
NOW
PLAYING
New Research Finds 1/3 of Breast Cancer Patients Experience Temporary or Lasting Depression Symptoms During & After Treatment
NOW
PLAYING
A SurvivorNet Guide to Early-Stage Cancer Detecting Blood Tests

SurvivorNetTV.
Hope. Science.
Inspiration.

WATCH NOW
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.